Understanding cancer risk with hormone therapy can feel confusing—especially with so much outdated or conflicting information online. Many concerns come from older studies that evaluated synthetic hormones, which are different from the bioidentical hormones used in Oestra®.
This guide explains what current research shows and how it relates specifically to Oestra© and its ingredients.
What Is Oestra©?
Oestra© is a bioidentical hormone therapy made with:
Plant-based estradiol
Micronized progesterone
These hormones are structurally identical to those naturally produced by your body.
It is delivered in a vaginal cream base, designed to:
Support local absorption through vaginal tissue
Minimize unnecessary systemic exposure
Be gentle on sensitive tissue and the vaginal microbiome
Breast Cancer Risk: What Applies to Oestra©
Much of the fear around hormone therapy comes from older studies using synthetic progestins, not bioidentical progesterone.
What research shows:
Estrogen combined with micronized (bioidentical) progesterone has a more favorable breast safety profile than synthetic alternatives
The increased breast cancer risk seen in earlier studies is largely linked to non-bioidentical hormones
🔗 https://pubmed.ncbi.nlm.nih.gov/19179815/
Why this matters for Oestra©:
Oestra uses micronized progesterone, not synthetic progestins
This aligns with the type of hormone therapy shown to have lower associated breast risk
Estrogen + Progesterone Balance (Why Both Matter)
Oestra© includes both:
Estradiol (to relieve symptoms and restore balance)
Progesterone (to protect the uterine lining)
Key point:
Using estrogen alone can stimulate the uterine lining
Micronized progesterone helps protect against endometrial (uterine) cancer
This combination is considered the standard of care for women with a uterus.
Ovarian Cancer Risk
Some studies suggest a very small increase in ovarian cancer risk with long-term hormone use, but:
The absolute risk is low
Findings are not specific to bioidentical vaginal formulations
🔗https://pubmed.ncbi.nlm.nih.gov/28703650/
Does Route of Delivery Matter? (Why Vaginal Use Is Important)
Oestra© is delivered vaginally, which is different from oral or systemic hormone therapy.
Vaginal delivery may:
Provide targeted tissue absorption
Require lower doses
Reduce unnecessary systemic exposure
While research is still evolving, localized delivery is often considered a more conservative and tissue-specific approach.
Modern Research Perspective on Hormone Therapy
More recent studies emphasize that hormone therapy should be viewed in context—not just risk.
Potential benefits include:
Improved quality of life
Support for vaginal and urinary health
Bone and metabolic support
Reduced inflammation
🔗https://pubmed.ncbi.nlm.nih.gov/37209498/
Safety & Formulation Matter
Not all “bioidentical” therapies are the same.
Oestra© is designed with:
Standardized bioidentical hormones
A clean, hypoallergenic base
No endocrine disruptors or preservatives
A 2020 review highlights that quality, formulation, and medical oversight are key factors in safety.
🔗 https://pubmed.ncbi.nlm.nih.gov/32636633/
Key Takeaways
Cancer risk varies based on type of hormone, not just “HRT” as a category
Micronized progesterone (used in Oestra©) has a more favorable safety profile than synthetic alternatives
Vaginal delivery offers a targeted, lower-exposure approach
Individual risk depends on:
Personal health history
Age and timing
Duration of use
A Balanced Perspective
No medical treatment is completely without risk—but neither is untreated hormone imbalance.
The goal with Oestra© is to:
Use bioidentical, body-matched hormones
Deliver them in a gentle, targeted way
Support your body while minimizing unnecessary risk
Final Thoughts
If you’re considering Oestra© or have concerns about cancer risk, the best next step is a personalized conversation.
Our clinical team can help you:
Review your individual risk factors
Understand your options
Make a decision that feels informed and aligned with your health goals
Please reach out in your secure chat with any questions, we’re here to support you every step of the way!
References
1. Bioidentical Progesterone and Breast Cancer Risk
Fournier A, Berrino F, Clavel-Chapelon F.
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
Breast Cancer Research and Treatment. 2008.
PMID: 19179815
https://pubmed.ncbi.nlm.nih.gov/19179815/
Summary: This large prospective cohort study found that estrogen therapy combined with micronized (bioidentical) progesterone was associated with a significantly lower breast cancer risk than estrogen combined with synthetic progestins.
2. Menopausal Hormone Therapy and Ovarian Cancer
Collaborative Group on Epidemiological Studies of Ovarian Cancer.
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
PMID: 28703650
https://pubmed.ncbi.nlm.nih.gov/28703650/
Summary: This analysis evaluated ovarian cancer risk associated with menopausal hormone therapy and found that any increase in absolute risk is small. The study primarily evaluated traditional hormone therapy formulations and was not specific to vaginal bioidentical therapies.
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS)
The North American Menopause Society.
The 2022 hormone therapy position statement of The North American Menopause Society.
Menopause. 2022.
PMID: 35797481(The official NAMS Position Statement; note that this differs from the PMID you originally listed.)
https://pubmed.ncbi.nlm.nih.gov/35797481/
Summary: This evidence-based guideline concludes that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. It supports individualized treatment based on age, health history, timing of initiation, and shared decision-making.
Note: The PMID 37209498 that you provided is a different publication. If your intention was to cite the official NAMS Position Statement, the correct PubMed ID is 35797481.
4. Menopausal Hormone Therapy: Benefits and Risks
L'Hermite M.
Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
PMID: 32636633
https://pubmed.ncbi.nlm.nih.gov/32636633/
Summary: This review discusses the safety and efficacy of bioidentical hormone therapy, highlighting the favorable evidence supporting transdermal or vaginal estradiol combined with micronized progesterone compared with older synthetic hormone formulations.
Additional Trusted Clinical Resource (Recommended)
The Menopause Society (formerly North American Menopause Society)
Evidence-based information for patients and healthcare professionals.
https://menopause.org/
Medical Disclaimer: This article is intended for educational purposes only and summarizes findings from published medical literature. Every woman's health history is unique. Treatment decisions should always be made in consultation with a qualified healthcare provider who can assess your individual risks and benefits.